Larimar Therapeutics Files 8-K
Ticker: LRMR · Form: 8-K · Filed: May 30, 2024 · CIK: 1374690
| Field | Detail |
|---|---|
| Company | Larimar Therapeutics, Inc. (LRMR) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Larimar Therapeutics filed an 8-K on 5/30/24, standard disclosure.
AI Summary
Larimar Therapeutics, Inc. filed an 8-K on May 30, 2024, to report other events and financial statements. The company, formerly known as Zafgen, Inc., is incorporated in Delaware and is in the pharmaceutical preparations industry.
Why It Matters
This filing indicates a routine update on company events and financial disclosures, providing transparency for investors.
Risk Assessment
Risk Level: low — This is a routine filing reporting other events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 001-36510 — SEC File Number (Company's SEC filing identifier)
- 20-3857670 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Larimar Therapeutics, Inc. (company) — Registrant
- Zafgen, Inc. (company) — Former Name
- May 30, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
FAQ
What is the primary purpose of this 8-K filing for Larimar Therapeutics, Inc.?
The primary purpose is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 30, 2024.
When was this 8-K report filed with the SEC?
The report was filed on May 30, 2024.
What was Larimar Therapeutics, Inc. formerly known as?
Larimar Therapeutics, Inc. was formerly known as Zafgen, Inc.
In which state is Larimar Therapeutics, Inc. incorporated?
Larimar Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Larimar Therapeutics, Inc.?
The principal executive office is located at Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004.
Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-30 16:08:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market
Filing Documents
- lrmr-20240530.htm (8-K) — 38KB
- lrmr-ex99_1.htm (EX-99.1) — 23KB
- img46574298_0.jpg (GRAPHIC) — 276KB
- 0000950170-24-066571.txt ( ) — 531KB
- lrmr-20240530.xsd (EX-101.SCH) — 23KB
- lrmr-20240530_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On May 30, 2024, Larimar Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on May 30, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: May 30, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer